EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

[News]

Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended a positive opinion for the marketing authorization of XGEVA (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors.

More... (http://www.news-medical.net/news/20110520/EMA-CHMP-recommends-positive-opinion-for-marketing-authorization-of-Amgens-XGEVA.aspx)